Gene Expression Profiling of Homologous Recombination Repair Predicts PARP Inhibitor Sensitivity in Malignant Pleural Mesothelioma

Study Background and Research Question

Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited responsiveness to standard chemotherapy regimens such as cisplatin and pemetrexed, yielding unsatisfactory response rates of approximately 40% (Borchert et al., 2019). The mechanisms underlying frequent therapeutic resistance remain incompletely understood. One suspected contributor is the role of DNA repair pathways, particularly the homologous recombination repair (HRR) system, in enabling tumor cell survival despite DNA-damaging agents. The reference study by Borchert et al. addresses a critical question: Can profiling gene expression within the HRR pathway, specifically features of the so-called "BRCAness" phenotype, identify MPM tumors likely to benefit from poly(ADP-ribose) polymerase (PARP) inhibition—most notably by olaparib?

Key Innovation from the Reference Study

The central innovation of Borchert et al. is the comprehensive integration of in vitro drug response data with gene expression profiling of HRR and BRCAness-related genes in MPM. By correlating molecular signatures with cellular phenotypes, the authors move beyond mutation-centric approaches (e.g., BRCA1/2 status) and propose a functional, expression-based method to stratify tumors according to their likely response to PARP inhibition (Borchert et al., 2019). This enables identification of a broader subset of patients who might benefit from such targeted therapies.

Methods and Experimental Design Insights

Borchert et al. employed a dual approach:

1. Cellular Models: Three human MPM cell lines were assessed for sensitivity to pemetrexed, cisplatin, and olaparib, with lung fibroblasts serving as non-malignant controls. Among these, NCI-H2452 harbors a BAP1 mutation—a marker associated with BRCAness.
2. Gene Expression Analysis: The HRR gene expression landscape was profiled in 91 clinical MPM samples. The team focused on genes previously implicated in double-strand break repair and the BRCAness phenotype, including not only BRCA1/2 but also BAP1, RAD50, AURKA, and DDB2.

Drug responses were quantified by measuring apoptosis and senescence markers following treatment. Correlations between gene expression patterns and drug sensitivity were statistically analyzed.

Core Findings and Why They Matter

Borchert et al. report several significant findings:

1. BRCAness as a Functional Biomarker: MPM cell lines exhibiting BRCAness features—especially those with BAP1 mutations—showed increased apoptosis and senescence upon olaparib treatment, validating the concept that HRR deficiency sensitizes cells to PARP inhibition (Borchert et al., 2019).
2. Prevalence in Clinical Samples: The relevant gene expression signature was found in approximately 10% of patient-derived tumor samples, suggesting that a meaningful subset of MPM patients may be candidates for PARP inhibitor therapy.
3. Predictive Markers Identified: Expression levels of AURKA, RAD50, and DDB2 were identified as prognostic markers, providing a potential framework for patient stratification.
4. Combination Therapy Potential: The greatest response to olaparib was observed in BAP1-mutated NCI-H2452 cells, especially when combined with cisplatin, hinting at a synergistic effect that could be relevant for up to two-thirds of patients depending on their HRR status.

These findings reinforce a growing body of evidence that the DNA damage response—specifically the HRR pathway—can be exploited therapeutically in cancers beyond those with canonical BRCA1/2 mutations. The study also aligns with broader research into apoptosis induction in cancer cells by manipulating DNA repair and cell death signaling.

Protocol Parameters

• apoptosis induction assay | Annexin V/PI staining, flow cytometry | MPM cell lines (e.g., NCI-H2452) | Quantitative assessment of apoptosis after olaparib ± cisplatin | paper
• gene expression profiling | qRT-PCR, microarray | 91 MPM clinical samples | Identify BRCAness/HRR gene signatures | paper
• drug treatment concentration | 1–10 μM olaparib, 10 μM cisplatin | in vitro MPM models | Dose response for apoptosis/senescence analysis | paper
• calcium ionophore inclusion | 0.5–2 μM ionomycin calcium salt | cell signaling/apoptosis pathway studies | To modulate intracellular Ca2+ and probe calcium signaling effects on apoptosis | workflow_recommendation
• BAP1 mutation status screening | immunohistochemistry, sequencing | stratify MPM cell lines | Identify BRCAness phenotype | paper

Comparison with Existing Internal Articles

Recent internal articles have highlighted the utility of calcium ionophores, such as Ionomycin calcium salt, in dissecting apoptotic pathways and calcium signaling in cancer models:

• "Ionomycin Calcium Salt: Precision Modulator of Calcium Signaling" (etripamilpharma.com) discusses ionomycin’s role in controlled intracellular Ca2+ elevation, which can impact cell death mechanisms, including apoptosis induction in cancer cells—a mechanistic theme that parallels the apoptosis observed upon PARP inhibition in MPM.
• "Ionomycin Calcium Salt: Precision Calcium Ionophore for In Vivo and In Vitro Cancer Research" (ionomycin-calcium-salt.com) emphasizes validated workflows for using ionomycin to probe calcium-dependent apoptosis and tumor inhibition, providing methodological context for similar studies involving DNA repair and cell death pathways.

These resources suggest complementary experimental avenues for investigating how calcium signaling intersects with DNA repair and apoptosis, as highlighted in the reference study.

Limitations and Transferability

While Borchert et al. provide compelling in vitro data, several limitations must be noted:

• Translational Gap: The study primarily uses cell lines and gene expression data from tumor samples, lacking direct in vivo validation of PARP inhibitor efficacy in MPM patients.
• Patient Subset Size: Only about 10% of tumors exhibited the full BRCAness expression signature, potentially limiting the broad applicability of this approach.
• Complex Mechanisms: HRR deficiency is only one determinant of PARP inhibitor sensitivity; alternative DNA repair pathways and tumor microenvironment effects may modulate response.

Nevertheless, the approach of functional gene expression profiling for therapy selection represents a mature and promising strategy, albeit one that requires further clinical validation.

Research Support Resources

Researchers seeking to explore the calcium signaling pathway’s influence on apoptosis, DNA repair, or chemotherapy sensitization may consider incorporating calcium ionophores into their protocols. For example, Ionomycin calcium salt (SKU B5165, APExBIO) is a well-characterized calcium ionophore that enables rapid, controlled elevation of intracellular Ca2+—an approach that can facilitate mechanistic studies of apoptosis induction in cancer cells and modulation of pathways such as Bcl-2/Bax (workflow_recommendation). For detailed experimental design and validated application workflows, researchers are advised to consult both the primary literature and scenario-driven guides available through internal resources.